Ultragenyx Pharmaceutical Inc
The goal of this study is to assess the safety and dose of UX016 and its impact on muscle strength in adults with GNE Myopathy (GNEM).
Inclusion Criteria: * A confirmed diagnosis of GNEM (also known as distal myopathy with rimmed vacuoles \[DMRV\], hereditary inclusion body myopathy \[HIBM\], inclusion body myopathy 2 \[IBM2\], and Nonaka myopathy in Japan) by Clinical Laboratory Improvement Amendments (CLIA)-certified genetic testing with identification of a disease-associated variant in the gene encoding the GNE/MNK enzyme. Genotyping will not be conducted in this protocol * Ability to walk a minimum of 20 m independently during Screening. The use of assistive devices and orthotics is allowed. * Has ≤ 80% of normal biceps…
Tablets for oral use
Tablets for oral use. Tablets will match the UX016 tablets, but contain no active ingredients
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.